Neotropix, Inc. Announces Presentation of Relevant Preclinical Results of NTX-010 in Pediatric Oncology Models
10/22/2008 8:44:52 AM
MALVERN, PA--(Marketwire - October 22, 2008) - Neotropix®, Inc., a clinical-stage development company focused on neuroendocrine cancer treatments, announced today exciting data from an extensive pediatric preclinical study performed by the National Cancer Institute (NCI) funded Pediatric Preclinical Testing Program on the use of NTX-010 (Seneca Valley Virus-001), a tumor-selective naturally-occurring oncolytic virus. The results support the initiation of clinical development of Neotropix's lead candidate, NTX-010 for the treatment of pediatric cancers. NTX-010 has been developed as a cancer therapeutic to treat some of the most aggressive cancers known which occur in adults including small cell lung cancer, large cell non-small cell lung cancer, as well as other adult cancers such as carcinoid and various neuroendocrine cancers.
comments powered by